DOJ and Walmart’s $50 Million Opioid Settlement: The Dollar Figure is Not the Real Story
By: Hunter DeKoninck
This post is for general informational purposes and does not constitute legal advice.
On August 28, 2026, Walmart agreed to pay $50 million to resolve DOJ’s civil lawsuit, which accused the company of violating the CSA by filling thousands of unlawful opioid prescriptions and failing to report suspicious orders to DEA. Most media coverage on this settlement seems to be focused on the $50 million figure, which is a fraction of what DOJ’s complaint suggested Walmart was exposed to. But, in my view, the far more interesting story is what the settlement represents when we zoom out and view it in proper context—this is a case that started in 2020 as a sweeping challenge to Walmart’s entire compliance program and hold a company civilly liabile at the corporate level, it was later substantially cut down by a federal court ruling in 2024 and, as a result of that 2024 ruling, the parties were left with a much narrower case involving a very difficult legal standard, encouraged both parties to prefer settlement over a verdict.
The History of the Dispute
Walmart’s opioid dispensing practices had been under federal investigation out of the Eastern District of Texas since 2016. In an unusual defensive move, anticipating that DOJ would inevitably file a civil case against it, Walmart preempted DOJ by filing its own civil case.
October 22, 2020: Walmart sued first. It filed a declaratory judgment action against DOJ and DEA in the Eastern District of Texas, asking the court to clarify pharmacists’ obligations under the CSA. Walmart’s argument was that “every individual pharmacist must make the decision to refill a prescription or not.” This is the theory Walmart would use throughout the litigation—CSA compliance is an individual pharmacist’s professional judgment call, not a corporate function.
December 22, 2020: DOJ answered with its own suit, filed in the District of Delaware (Walmart’s state of incorporation). DOJ alleged CSA violations dating back to June 2013, built on two theories: (1) corporate compliance staff and individual pharmacists knowingly filled thousands of invalid prescriptions from prescribers that Walmart’s own pharmacists had flagged internally — DOJ alleged the company had received thousands of its own “refusal-to-fill” reports that corporate compliance staff didn’t act on and (2) Walmart’s distribution centers received hundreds of thousands of suspicious controlled-substance orders that went unreported to DEA. DOJ’s complaint pegged potential penalties at up to $67,627 per unlawful prescription and $15,691 per unreported suspicious order under 21 U.S.C. § 842(c). When these figures were multiplied across the volumes DOJ alleged, the case appeared to carry multi-billion-dollar exposure.
February 5, 2021: The Eastern District of Texas dismissed Walmart’s declaratory judgment suit.
December 22, 2021: The Fifth Circuit affirmed the dismissal of Walmart’s suit on two independent grounds: (1) Walmart hadn’t identified any final, challengeable “agency action” under the Administrative Procedure Act (only “negotiating positions,” which “are not binding on the regulated public”), and (2) the claim wasn’t ripe given the parallel Delaware litigation already testing the same theories. Walmart Inc. v. Dep’t of Justice, No. 21-40157 (5th Cir. Dec. 22, 2021).
November 2022: Separate from Walmart’s dismissed case and DOJ’s civil case pending in Delaware, Walmart agreed to pay $3.1 billion as part of a combined roughly $10 billion settlement with CVS and Walgreens resolving public-nuisance claims brought by states and local governments over the opioid epidemic. That settlement ran on state-law public-nuisance theories in the multidistrict opioid litigation, not the CSA, and it didn’t resolve or otherwise touch DOJ’s Delaware suit.
March 2024: In the Delaware matter, the federal court dismissed DOJ’s suspicious order reporting theory outright, holding that the civil penalty provision DOJ relied on did not reach the reporting conduct at issue for the period alleged. In short, Congress did not add an express suspicious order reporting requirement to the CSA until it did so through the 2018 SUPPORT Act. In other words, prior to 2018, the requirement was strictly administrative. Thus, DOJ was, in effect, trying to penalize pre-2018 conduct under a requirement that was not contained within the CSA. The court also dismissed the “red flags” theory (that pharmacists failed to identify, resolve, and document red flags associated with the prescriptions they filled). What survived the court’s order was a much narrower case—a claim that Walmart knowingly filled prescriptions that were legally ineffective.
August 28, 2026: DOJ and Walmart settle. $50 million, no admission of liability, plus prospective commitments: an employee/patient hotline for reporting suspected illegal dispensing, pharmacy dispensing-pattern monitoring, and a process for evaluating prescribers suspected of unlawful prescribing.
What the Fight Was Actually About
Ultimately, this was a fight over who bears the CSA compliance burden inside a national pharmacy chain. Walmart’s position was that the individual pharmacist’s professional judgment is the compliance mechanism, consistent with how the corresponding responsibility doctrine is usually applied to the pharmacist standing at the counter. DOJ’s theory was that a chain’s compliance obligation runs through its corporate systems, including its internal red-flag and refusal-to-fill reporting mechanisms, the staffing and productivity pressure placed on pharmacists, and its distribution centers’ suspicious order monitoring obligations. DOJ’s position was that a corporation cannot simply point to “the pharmacist decided to dispense” when its own systems allegedly generated, and ignored, thousands of internal red flag signals.
DOJ’s theory in this case is meaningfully different and more ambitious than the individual pharmacist and individual registrant corresponding responsibility case we typically see. This was DOJ attempting to hold a corporate parent civilly liable under § 842 for a systemic failure.
The March 2024 ruling rejected two of DOJ’s three system-focused theories, which left DOJ with the narrower claim that the company knew specific prescriptions were unlawful and filled them anyway.
What a Trial Verdict Could Have Meant for the Industry
A DOJ win on the narrowed claim would have been the first real litigated test of how far corporate-level CSA liability under § 842(a)(1) extends when the actual dispensing decisions are made by thousands of individually licensed pharmacists — a template DOJ could point to in other multi-location chain-pharmacy investigations working through the system.
A Walmart win would have been a significant setback for DOJ’s ability to build “knowing” claims against corporate defendants using evidence on internal compliance systems (refusal-to-fill data, staffing complaints, etc.). This would have established that liability for dispensing decisions rests with the dispensing pharmacist and cannot extend to the corporation for its related compliance practices.
A district court trial verdict, whichever way it went, would not have created binding precedent for the rest of the country, but it certainly would have reshaped settlement leverage for every other chain pharmacy facing similar civil action from DOJ.
My Read
The settlement figure making headlines is misleading if read in isolation. In reality, $50 million does not represent what a “knowingly filling invalid prescriptions” case is worth. Instead, I believe it is a figure unique to a decade-long dispute between the government and a chain pharmacy, where both sides were left agreeing that resolution now was much preferred over a trial about a narrow, hard-to-prove knowledge standard. DOJ’s public statement frames this as a win that reflects continued accountability, while Walmart frames it as immaterial and non-admissive. Both are true, and both are spin.
In my view, the settlement is not the most interesting outcome of this case. Rather, it is the court’s March 2024 ruling that the suspicious order reporting penalty provision could not reach pre-2018 conduct. For a variety of reasons, this is worth more to the industry going forward than the number others are writing about.
What the Settlement Leaves Unresolved
No clarity on the viability of DOJ’s “knowingly filled legally ineffective prescriptions” theory or its broader theory on corporate-level knowledge. DOJ will likely test these theories again in the future.
The court’s suspicious order ruling stands. Other courts are not bound by this court’s ruling, so expect DOJ to keep testing similar theories elsewhere, likely with more careful approaches to the arguments.
The settlement’s prospective terms (a hotline, dispensing-pattern monitoring, and a prescriber-evaluation process) appear to reflect what DOJ may expect from a large chain’s compliance program going forward. Other chain pharmacies should expect DOJ to pursue these types of compliance measures in future disputes.
Because there was no trial, there’s no public evidentiary record beyond the pleadings, which means much of what DOJ said it could prove (the volume of refusal-to-fill reports, the internal pressure on pharmacists) was never actually tested.
Bottom Line
Six years of litigation, two federal courts, a Fifth Circuit ruling on Walmart’s preemptive lawsuit, and a district court’s consequential ruling later, this case was resolved the same way almost any other CSA civil case is: a negotiated monetary amount and prospective compliance commitments. For pharmacies and distributors, the case is a reminder that DOJ’s theories of corporate-level CSA liability are still being tested and narrowed, and that the compliance commitments Walmart just agreed to are a preview of what DOJ will likely expect from the other chains it goes after.
If your organization is facing a DOJ or DEA inquiry into dispensing practices, suspicious order monitoring, or corporate compliance systems, reach out to DeKo Law LLC.
